Distribution controls updated for DSCSA and EU GDP
Ergopharm has completed a scheduled review of its distribution controls in light of two regulatory instruments issued in late 2013: the United States Drug Supply Chain Security Act, signed into law on 27 November 2013, and the European Union's revised Good Distribution Practice Guidelines, 2013/C 343/01. The review confirms that Ergopharm's own dispatch, storage and traceability procedures are aligned with the expectations set out in both frameworks.
The DSCSA was enacted as Title II of the Drug Quality and Security Act (Public Law 113-54). Over a phased timeline it establishes requirements for product identification, tracing and verification across the US supply chain, built on the interoperable, unit-level identification of prescription products and the exchange of transaction information between trading partners. As an export manufacturer, Ergopharm has reviewed how its batch documentation and product-identifier practices support the transaction records that downstream US trading partners will be required to receive and retain.
“Ergopharm's aim is that every pack can be traced and verified through the distribution channel while remaining within its labelled storage conditions.”
In the European Union, the Guidelines on Good Distribution Practice of medicinal products for human use (2013/C 343/01) were published on 5 November 2013, replacing the earlier 1994 text. The revised guidance sets clearer expectations for quality-system governance, qualification of suppliers and customers, temperature control and monitoring during storage and transport, the handling of returns and suspected falsified products, and the oversight of transport carried out by third parties. Ergopharm has mapped its warehouse, dispatch and cold-chain procedures against these chapters to confirm that goods leaving the facility remain traceable and are held within their labelled storage conditions throughout the distribution channel.
Practically, the review covered Ergopharm's serialisation readiness and its shipping controls. Packs continue to carry a GS1 DataMatrix (ECC200) encoding the GTIN, expiry, batch and serial, with cases and pallets identified by SSCC and linked through aggregation records, so that a shipment can be resolved from pallet to individual pack. Temperature-sensitive consignments are prepared under validated 2–8 °C cold-chain procedures with monitoring, and shipping terms are set under Incoterms 2020 with a WHO Certificate of a Pharmaceutical Product available to support export trade.
The exercise was documented through Ergopharm's own quality system, using change control to record the procedural updates and a management review to confirm ownership and follow-up. The company continues to align its packaging and distribution processes with these frameworks as their phased provisions come into force, without asserting any specific national marketing approval.
Key facts
- US DSCSA signed
- 27 November 2013 (Title II, DQSA, PL 113-54)
- EU GDP Guidelines
- 2013/C 343/01, published 5 November 2013
- Serialisation
- GS1 DataMatrix (ECC200); SGTIN packs, SSCC cases/pallets
- Cold chain
- Validated 2–8 °C storage and transport with monitoring
This notice describes Ergopharm’s own packaging and processes and how they follow published standards; it does not assert a specific national marketing approval.